Stereotaxis (NYSE:STXS) announced today that it has entered into a collaboration with Abbott (NYSE:ABT) to take robotic electrophysiology to the next level.
The collaboration aims to integrate the Abbott EnSite X EP system — a 3D heart mapping system — with Stereotaxis’ robotic magnetic navigation systems. Bringing the Abbott cardiac mapping system together with Stereotaxis’ robotic technology could enhance robotic surgery in the electrophysiology space.
The companies described the partnership as providing detailed, real-time diagnostic information with the precision and stability of robotics during therapy delivery.
According to the companies, technology integration enhances the physician experience and streamlines procedural workflow. It also supports the improved treatment of patients with abnormal heart rhythms, according to a news release.
The Abbott EnSite X system received FDA clearance in 2021. It creates highly detailed, three-dimensional maps of the heart, helping physicians identify and then treat areas where abnormal rhythms originate. Stereotaxis’ robotic magnetic navigation uses computer-controlled magnetic fields for direct control of a catheter tip in cardiac ablation.
Stereotaxis and Abbott say they successfully completed technology integration and performed testing demonstrating joint compatibility. Their technologies hold clearance for use in Europe, and the companies expect additional clearances in the coming months.
Dr. J. Peter Weiss called the combination of the technologies “a seminal event” in robotic electrophysiology. Weiss, an electrophysiologist and clinical professor of medicine at Banner University of Arizona Medical Center, said joint use of the platforms is “beneficial for the broad spectrum of cardiac ablation.”
“Stereotaxis is delighted to collaborate with Abbott and to be able to share this significant milestone for the electrophysiology field,” said David Fischel, chair and CEO of Stereotaxis. “This collaboration further reinforces our commitment to meaningful innovations that advance the frontiers of medical progress. It provides additional choice for the community of robotic users and ensures patients, physicians and providers can benefit from the combination of the finest diagnostic and therapeutic technologies.”
